13F-HR filed by TCG Crossover Management, LLC
TCG Crossover Management, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 43 holding rows worth $3,021,699,270.
- Accession
- 0001214659-26-001871
- Filer
- CIK 1839948
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 43 entries on the cover page, a total value of $3,021,699,270 stated on the cover page (in dollars after the unit check, H1), rows summing to $3,021,699,270 with VALUE read as dollars as filed, 13F file number 028-22283. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 7,111,596 | $959,034,279 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 5,868,162 | $208,437,114 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 3,670,206 | $152,386,953 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 12,762,094 | $113,072,153 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 4,286,480 | $107,204,865 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 4,615,144 | $90,272,217 | dollars as filed | |
| RAPT THERAPEUTICS INC | 75382E208 | COM NEW | 2,582,408 | $87,466,159 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 2,898,103 | $76,191,128 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 6,243,812 | $75,425,249 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 12,362,205 | $74,544,096 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 4,622,151 | $72,475,328 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 5,740,231 | $69,686,404 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 1,676,624 | $69,093,675 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 3,572,335 | $65,266,560 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 920,857 | $64,045,604 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 1,900,582 | $62,263,066 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 5,250,000 | $59,377,500 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 1,710,084 | $58,980,797 | dollars as filed | |
| BIOHAVEN LTD | G1110E107 | COM | 4,631,317 | $52,287,569 | dollars as filed | |
| IMMUNOVANT INC | 45258J102 | COM | 1,660,933 | $42,220,917 | dollars as filed | |
| KODIAK SCIENCES INC | 50015M109 | COM | 1,445,538 | $40,417,243 | dollars as filed | |
| ADC THERAPEUTICS SA | H0036K147 | COMMON STOCK | 11,390,175 | $40,207,318 | dollars as filed | |
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 1,745,015 | $38,844,034 | dollars as filed | |
| XENCOR INC | 98401F105 | COMMON STOCK | 2,452,138 | $37,542,233 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 436,473 | $34,765,074 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 1,181,841 | $32,169,712 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 2,666,216 | $31,621,322 | dollars as filed | |
| RELAY THERAPEUTICS INC COM | 75943R102 | Stock | 3,220,186 | $27,242,774 | dollars as filed | |
| JANUX THERAPEUTICS INC | 47103J105 | COM | 1,789,617 | $24,696,715 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 2,088,392 | $21,468,670 | dollars as filed | |
| MBX BIOSCIENCES INC COM | 55287L101 | Stock | 650,000 | $20,501,000 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 743,886 | $20,196,505 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 3,033,560 | $18,444,045 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 717,347 | $16,800,267 | dollars as filed | |
| ALECTOR INC | 014442107 | COMMON STOCK | 10,000,000 | $15,600,000 | dollars as filed | |
| MONOPAR THERAPEUTICS INC | 61023L207 | COMMON STOCK | 141,915 | $9,267,050 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 483,000 | $8,771,280 | dollars as filed | |
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 173,816 | $7,201,197 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 62,049 | $4,901,251 | dollars as filed | |
| LeonaBio Inc | 04746L203 | COM | 464,398 | $3,348,507 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 416,301 | $3,334,571 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 316,195 | $2,855,241 | dollars as filed | |
| VISTAGEN THERAPEUTICS INC | 92840H400 | COM | 2,676,580 | $1,771,628 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-26-001871 | this filing | 2026-02-17 | acceptance time not in the bulk data set |